NeOnc Technologies Holdings, Inc. NTHI 深 沪
已收盘 09-19 16:00:00 美东时间
11.99
-0.100
-0.83%
华盛通- 最 高12.435
- 今 开12.20
- 成交量 65.99万股
- 最 低 11.1001
- 昨 收 12.09
- 总市值 2.28亿
- 52周最高 25.00
- 市盈率 静 --
- 换手率 3.47%
- 52周最低 3.20
- 委 比 -34.43%
- 总股本 1902.68万
- 历史最高 25.00
- 量 比 4.96
- 振 幅 11.04%
- 历史最低 3.20
- 每 手 1
- 风险率 2.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA Authorizes NeOnc Technologies To Proceed With Phase IIa/IIb Of NEO212-01 Clinical Trial
NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced that the
09-10 21:07
Blue Gold Appoints Quazar’s Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy
Blue Gold Limited announced the appointment of Sameer Salgar, Founding Partner and Chief Financial Officer of Quazar Investment, to its Advisory Board. With over 20 years of experience in investment and corporate finance, Salgar will help Blue Gold expand its digital gold platform and strengthen ties with the UAE. Quazar Investment will assist in developing digital technology solutions, establishing gold vault infrastructure in the UAE, and conne...
09-10 13:40
NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer
NeOnc Technologies Holdings, Inc. announced FDA authorization to advance its NEO212-01 clinical trial into Phase IIa/IIb following successful Phase I results. NEO212, a novel oral chemotherapy drug combining Temozolomide with NEO100, aims to overcome limitations of current glioblastoma treatments. The company plans to expand Phase II trials across leading U.S. cancer centers, positioning NEO212 as a potential new standard of care for brain cancer...
09-10 13:00
NeOnc Completes Acquisition and Board Reshuffle
The latest update is out from NeOnc Technologies Holdings, Inc. ( ($NTHI) ). On...
08-23 05:32
NeOnc Technologies Holdings GAAP EPS of $0.30
NeOnc Technologies Holdings press release (NASDAQ:NTHI): Q2 GAAP EPS of $0.30. G&A expenses: $984K vs. $290K in Q2 2024, reflecting expanded marketing, rent, travel, and Middle East partnership-relate...
08-20 03:35
NeOnc Technologies Q2 EPS $(0.30) Down From $(0.27) YoY
NeOnc Technologies (NASDAQ:NTHI) reported quarterly losses of $(0.30) per share. This is a 11.11 percent decrease over losses of $(0.27) per share from the same period last year.
08-19 21:22
NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) reported its Q2 2025 financial results and highlighted recent achievements. Key points include securing a $50 million partnership with Quazar Investment, securing $2.5 million in NIH grants, acquiring advanced AI and quantum modeling IP, and expanding its clinical trials. The company also joined the Russell Microcap Index, appointed Dr. Josh Neman as CCO, and advanced its pipeline with Phase 2 tria...
08-19 13:00
NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation
NeOnc Technologies and Quazar Investment announced the incorporation of NuroMENA Holdings Ltd. in Abu Dhabi, finalizing a $50 million investment led by Quazar to support NeOnc’s CNS cancer therapies in the MENA region. This collaboration aims to accelerate clinical programs NEO212 and NEO100, marking a pivotal step for NeOnc and Quazar in advancing innovative treatments for brain cancer and CNS disorders across the Middle East and North Africa.
08-11 13:00
NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia
<p>NeOnc Technologies Holdings, Inc. announced the award of two NIH STTR grants totaling $2.5 million to advance the development of NEO212, a therapeutic compound in Phase 1 clinical trials. The grants include a $400,000 Phase 1 grant for AML studies led by Dr. Thomas Chen and Dr. Axel Schönthal, and a $2.1 million Phase 2 grant focused on gliomas led by Dr. Chen and Dr. Radu Minea. These funds highlight NEO212's potential and NeOnc's collaborati...
08-07 13:00
NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer
NeOnc Technologies Holdings, Inc. (NTHI) featured on Yahoo Finance’s *Trader Talk* podcast, discussing its challenges and achievements, including securing a $50 million partnership and joining the Russell Microcap Index. The company focuses on intranasal drug delivery for brain cancer, leveraging AI and quantum computing for innovation. Its NEO100 and NEO212 therapeutics are in Phase II clinical trials with FDA Fast-Track status.
08-04 13:00
